Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3454738 for Moderate-to-Severe Atopic Dermatitis in Adults (J4E-MC-IMMB / J4E-MC-FR01)
2022-502888-38-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing LY3454738 with Placebo (2 arms). Primary endpoint: EASI-75 response. Started Aug 2023; status: completed.
02
Drugs
ucenprubart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-502888-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502888-38-00.